2005 Annual Meeting | Stroke Prevention in 2005

Date Sunday 04/10/05

Time 09:00 AM - 12:45 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type AM Half-Day Course

Director(s) Mitchell S. Elkind, MD, MS, FAAN

Topic(s) Cerebrovascular Disease and Interventional Neurology

Learning Objectives Upon completion:
Participants should be able to discuss and apply to patient care the latest clinical trial results regarding antithrombotic agents in stroke prevention, including aspirin, clopidogrel, dipyridamole, warfarin, and ximelagatran; discuss evidence linking inflammatory markers like high sensitivity C-reactive protein to risk of stroke; use markers of inflammation appropriately in the evaluation of stroke patients; decide how to use statin therapy in stroke patients; provide a rational approach to the medical management of patients with patent foramen ovale; interpret the data on PFO closure; and discuss the results of recent trials of carotid surgery and stenting.

CME Available No CME available

Program Level Advanced

Recommended Audience Practitioner, Fellow, Academician, Resident

Event Timeline
09:00 AM - 09:45 AM		The Current Science of Anti-Thrombotic Therapy Oscar R. Benavente, MD, FRCP(C)
09:45 AM - 10:30 AM		Lipoproteins, C-Reactive Protein and Inflammation: A Statin for Every Stroke Patient? Mitchell S. Elkind, MD, MS, FAAN
10:30 AM - 10:45 AM		Break
10:45 AM - 11:30 AM		Patent Foramen Ovale: To Close or Not to Close? Karen L. Furie, MD
11:30 AM - 12:15 PM		Carotid Endarterectomy and Stenting: When to Use Which Pierre Fayad, MD, FAHA, FAAN
12:15 PM - 12:45 PM		Questions and Answers

Faculty Disclosures
Mitchell S. Elkind, MD, MS, FAAN	Dr. Elkind has received personal compensation for serving as an employee of American Heart Association. Dr. Elkind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Atria Academy. The institution of Dr. Elkind has received research support from BMS-Pfizer Alliance for Eliquis. The institution of Dr. Elkind has received research support from Roche. Dr. Elkind has received publishing royalties from a publication relating to health care. Dr. Elkind has a non-compensated relationship as a Officer with American Heart Association that is relevant to AAN interests or activities.
Pierre Fayad, MD, FAHA, FAAN	Dr. Fayad has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. Dr. Fayad has received personal compensation in the range of $0-$499 for serving as a Member Data Safety & Monitoring Committee with NINDS.
Oscar R. Benavente, MD, FRCP(C)	No disclosure on file
Karen L. Furie, MD	The institution of Dr. Furie has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen/BMS. Dr. Furie has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for BMJ/JNNP. The institution of Dr. Furie has received research support from NINDS.